SABCS 2024 | Phase Ib/II trial of naxitamab, gemcitabine and TGFβi NKs in HER- breast cancer
Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, discusses a Phase Ib/II trial (NCT06026657) of naxitamab, an anti-GD2 monoclonal antibody, gemcitabine, with TGFβ-imprinted, IL-21 expanded NK cells (TGFβi NKs) in patient with HER2-negative breast cancer. By targeting immune suppression in the tumor microenvironment, this combination leverages NK cell activity and antibody-dependent cytotoxicity. Outcomes include response rates, progression-free survival, and immune biomarkers, with early preclinical data showing promising efficacy. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
